Table 3 Treatment-related adverse events
Treatment-related adverse events* | Grade 1–2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|
White blood cell count decreased | 18 (17.6%) | 1 (1.0%) | 1 (1.0%) | 0 |
Fever | 13 (12.7%) | 1 (1.0%) | 0 | 0 |
Anemia | 11 (10.8%) | 2 (2.0%) | 0 | 0 |
Lymphocyte count decreased | 6 (5.9%) | 3 (2.9%) | 1 (1.0%) | 0 |
Neutrophil count decreased | 9 (8.8%) | 0 | 1 (1.0%) | 0 |
Pruritus | 8 (7.8%) | 1 (1.0%) | 0 | 0 |
Platelet count decreased | 6 (5.9%) | 1 (1.0%) | 2 (2.0%) | 0 |
Pneumonitis | 6 (5.9%) | 0 | 1 (1.0%) | 0 |
Rash | 4 (3.9%) | 1 (1.0%) | 0 | 0 |
Abnormal liver function | 3 (2.9%) | 2 (2.0%) | 0 | 0 |
Hypertension | 3 (2.9%) | 1 (1.0%) | 0 | 0 |
Upper respiratory tract infection | 1 (1.0%) | 2 (2.0%) | 0 | 0 |
Infusion related reaction | 2 (2.0%) | 1 (1.0%) | 0 | 0 |
Lung infection | 0 | 2 (2.0%) | 0 | 0 |
Febrile neutropenia | 0 | 0 | 1 (1.0%) | 0 |
Hyponatremia | 0 | 1 (1.0%) | 0 | 0 |
Abdominal infection | 0 | 1 (1.0%) | 0 | 0 |
Infection | 0 | 2 (2.0%) | 0 | 0 |
Respiratory infection | 0 | 1 (1.0%) | 0 | 0 |
Abdominal pain | 0 | 1 (1.0%) | 0 | 0 |
Allergic reaction | 0 | 1 (1.0%) | 0 | 0 |
Hyperuricemia | 3 (2.9%) | 0 | 1 (1.0%) | 0 |
Hypokalemia | 2 (2.0%) | 0 | 1 (1.0%) | 0 |
Heart failure | 1 (1.0%) | 0 | 1 (1.0%) | 0 |
Autoimmune hemolytic anemia | 0 | 0 | 2 (2.0%) | 0 |
Autoimmune hepatitis | 0 | 0 | 1 (1.0%) | 0 |
Volvulus§ | 0 | 0 | 0 | 1 (1.0%) |
Death# | 0 | 0 | 0 | 1 (1.0%) |
Blood bilirubin increased | 1 (1.0%) | 0 | 1 (1.0%) | 0 |
Reticulocyte count increased | 0 | 1 (1.0%) | 0 | 0 |
Lymphopenia | 1 (1.0%) | 1 (1.0%) | 0 | 0 |
Weight loss | 2 (2.0%) | 1 (1.0%) | 0 | 0 |
Bone marrow hypocellular | 0 | 0 | 1 (1.0%) | 0 |
Neutropenia | 0 | 1 (1.0%) | 0 | 0 |